Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SLN 
Silence Therapeutics PLC (SLN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: SLN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 99.76% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 222.85M USD | Price to earnings Ratio - | 1Y Target Price 46.88 |
Price to earnings Ratio - | 1Y Target Price 46.88 | ||
Volume (30-day avg) 212533 | Beta 1.04 | 52 Weeks Range 2.37 - 24.38 | Updated Date 03/30/2025 |
52 Weeks Range 2.37 - 24.38 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.7 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1973.47% |
Management Effectiveness
Return on Assets (TTM) -27.27% | Return on Equity (TTM) -102.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12874703 | Price to Sales(TTM) 3.16 |
Enterprise Value 12874703 | Price to Sales(TTM) 3.16 | ||
Enterprise Value to Revenue 0.3 | Enterprise Value to EBITDA -5.78 | Shares Outstanding 47214800 | Shares Floating 77509280 |
Shares Outstanding 47214800 | Shares Floating 77509280 | ||
Percent Insiders 13.73 | Percent Institutions 55.57 |
Analyst Ratings
Rating 4.5 | Target Price 53.7 | Buy 3 | Strong Buy 3 |
Buy 3 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Silence Therapeutics PLC
Company Overview
History and Background
Silence Therapeutics PLC was founded in 1994, focusing on RNA interference (RNAi) therapeutics. Initially focused on gene silencing, it has evolved into a clinical-stage biopharmaceutical company developing novel mRNAi medicines.
Core Business Areas
- mRNAi Therapeutics: Focuses on developing medicines based on mRNAi technology, targeting specific genes to treat diseases.
Leadership and Structure
The leadership team consists of executives with experience in biotechnology and pharmaceuticals. The organizational structure includes research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- SLN360: SLN360 is an siRNA targeting lipoprotein(a) being developed for the treatment of cardiovascular disease. It is currently in Phase 3 clinical trials. Competitors include Novartis (NVS) and Amgen (AMGN) who are developing competing LPA lowering therapies, but this market is so large that multiple winners will be very successful.
- SLN124: SLN124 is an siRNA targeting TMPRSS6 being developed for the treatment of anemia. It is currently in Phase 2 clinical trials. Competitors include Acceleron Pharma (acquired by Merck - MRK) and Protagonist Therapeutics (PTGX), which are working on similar anemia treatments.
Market Dynamics
Industry Overview
The RNAi therapeutics industry is growing, driven by advancements in drug delivery and target identification. The market is characterized by high innovation and competition.
Positioning
Silence Therapeutics PLC is positioned as a leader in mRNAi technology, with a focus on developing targeted therapeutics. Its competitive advantage lies in its proprietary mRNAi platform.
Total Addressable Market (TAM)
The total addressable market for RNAi therapeutics is estimated to be in the tens of billions of dollars. Silence Therapeutics PLC is positioned to capture a significant share through its pipeline of novel therapies, especially in cardiovascular and hematological indications. Specific to LPA reducing drugs the total market is at least $10 Billion
Upturn SWOT Analysis
Strengths
- Proprietary mRNAi technology platform
- Strong pipeline of clinical-stage assets
- Experienced management team
- Partnerships with major pharmaceutical companies
Weaknesses
- Limited commercial infrastructure
- Reliance on clinical trial success
- Competition from established pharmaceutical companies
- High R&D costs
Opportunities
- Expanding pipeline through internal development and partnerships
- Addressing unmet medical needs in large therapeutic areas
- Advancements in drug delivery technology
- Potential for strategic acquisitions
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from novel therapies
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- ALNY
- IONS
- MRNA
Competitive Landscape
Silence Therapeutics PLC is a mid-sized player in the RNAi therapeutics market. It competes with larger pharmaceutical companies and specialized biotech firms. Its strengths are its mRNAi platform and clinical pipeline; its weaknesses are its limited commercial infrastructure and reliance on clinical trial success.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by advancements in its mRNAi platform and progress in its clinical pipeline.
Future Projections: Future growth is dependent on the success of clinical trials and the approval of its therapeutic candidates. Analyst estimates would be needed for precise projections.
Recent Initiatives: Recent initiatives include advancing SLN360 into Phase 3 trials and expanding its pipeline through collaborations and internal development.
Summary
Silence Therapeutics PLC is a promising biotech company focused on RNAi therapeutics. Its success hinges on the positive outcomes of its clinical trials, particularly for SLN360 and SLN124. The company should continue to strengthen partnerships and secure funding to support its ambitious R&D program. Competition in the RNAi space is intense, and regulatory hurdles pose potential challenges. Overall, Silence Therapeutics PLC has a good product profile and is well positioned in this market.
Similar Companies
ALNY
Alnylam Pharmaceuticals Inc
ALNY
Alnylam Pharmaceuticals Inc
IONS
Ionis Pharmaceuticals Inc
IONS
Ionis Pharmaceuticals Inc
MRNA
Moderna Inc
MRNA
Moderna Inc
Sources and Disclaimers
Data Sources:
- Silence Therapeutics PLC website
- SEC filings
- ClinicalTrials.gov
- Analyst reports (FactSet, Bloomberg) - requires subscription
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is approximate. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Silence Therapeutics PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-09-08 | President, CEO & Executive Director Mr. Craig A. Tooman M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 116 | |
Full time employees 116 | |||
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.